STAAR Surgical (NASDAQ:STAA) Receives $25.29 Consensus Price Target from Analysts

Shares of STAAR Surgical (NASDAQ:STAA) have been assigned an average recommendation of “Hold” from the ten research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $25.29.

A number of equities analysts have commented on the company. Stifel Nicolaus decreased their target price on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Mizuho downgraded STAAR Surgical from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. Stephens reiterated an “equal weight” rating and issued a $17.00 target price on shares of STAAR Surgical in a research note on Tuesday, March 18th. Canaccord Genuity Group lowered their price target on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Finally, Jefferies Financial Group downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.

Insiders Place Their Bets

In other news, major shareholder Broadwood Partners, L.P. purchased 8,221 shares of the stock in a transaction dated Thursday, January 16th. The shares were bought at an average cost of $21.50 per share, for a total transaction of $176,751.50. Following the transaction, the insider now owns 10,878,007 shares in the company, valued at $233,877,150.50. This trade represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have purchased 1,074,103 shares of company stock worth $17,900,948. 1.00% of the stock is owned by corporate insiders.

Institutional Trading of STAAR Surgical

Several institutional investors have recently modified their holdings of the company. Quarry LP acquired a new stake in STAAR Surgical in the 3rd quarter valued at about $50,000. Quest Partners LLC acquired a new stake in STAAR Surgical during the third quarter valued at approximately $128,000. KLP Kapitalforvaltning AS bought a new stake in STAAR Surgical during the fourth quarter worth approximately $180,000. Larson Financial Group LLC grew its position in STAAR Surgical by 78.3% in the third quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after buying an additional 2,135 shares during the last quarter. Finally, Bridgefront Capital LLC increased its holdings in shares of STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after buying an additional 2,306 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Stock Performance

NASDAQ STAA opened at $17.79 on Friday. STAAR Surgical has a one year low of $13.50 and a one year high of $52.68. The company has a 50-day simple moving average of $19.43 and a 200-day simple moving average of $25.23. The firm has a market capitalization of $877.49 million, a PE ratio of -43.39 and a beta of 0.66.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.